Exciting developments in cancer treatment were unveiled at the AACR meeting. Boehringer Ingelheim's zongertinib shows a 71% ...

The American Association for Cancer Research’s annual conference featured updates from several companies on key candidates ...

Announced rosnilimab, a depleter and agonist targeting PD-1+ T cells, achieved positive results in Phase 2b rheumatoid arthritis (RA) trial; to present updated clinical and translational data in the ...

Patients with certain types of early stage cancer, particularly those affecting the gastrointestinal system, may be able to ...

Announced rosnilimab, a depleter and agonist targeting PD-1+ T cells, achieved positive results in Phase 2b rheumatoid arthritis (RA) trial; to present updated clinical and translational data in the ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...

The increase is due to a $11.0 million increase in royalties recognized for sales of Jemperli and $9.6 million in revenue recognized for the Vanda license agreement. Research and development ...

Patients with some gastrointestinal tumors were able to be treated with immunotherapy drugs alone and avoid surgery, ...

Neoadjuvant PD-1 blockade in dMMR tumors "could potentially eradicate the need for chemotherapy, radiation, and surgery in ...

We expect GSK's specialty products like Cabenuva, Juluca, Dovato, Nucala, Ojjaara, Jemperli and Trelegy Ellipta to have driven first-quarter sales performance.

GSK has claimed US approval for Jemperli alongside chemotherapy for previously untreated, primary advanced or recurrent endometrial cancer, becoming the first immunotherapy option for first-line ...

A new study found that the immunotherapy treatment worked against some types of cancers, allowing patients to avoid surgery ...